11 December 2019
In the nutraceutical market, SOFAR has once again won top positions in the ranking of healthcare companies. We are in the top 10 companies in the healthcare industry and have a top-selling product in the gastrointestinal sector.
According to Parafarmacia, which published a July 2019 nutraceutical market analysis by IQVIA, which sheds light on the dynamics and developments of this specific market.
IQVIA’s data found that SOFAR, for the umpteenth time, ranks among the top 10 companies in the nutraceutical sector. Further, the report ranked our Enterolactis Plus as the fourth most-sold product ever.
In fact, in the gastrointestinal well-being market SOFAR is the top-ranking company, with Enterolactis Plus and Enterolactis winning first and fourth places, respectively, among the best-selling products.
In the Urology sector, our Cistiflux A Plus 36+D has also achieved a ranking of merit: it is the third most sold product.
Table drawn from the journal “Parafarmacia” n. 20 sept./oct. 2019
